FILING ANALYSIS · TUESDAY, NOVEMBER 3
Ultragenyx Pharmaceutical Inc. RARE — 8-K: Completion of Acquisition or Disposition of Assets
positive
Ultragenyx received $210 million from the sale of its Rare Pediatric Disease Priority Review Voucher, but will pay 20% of the gross proceeds to the NIH, and announced a restructuring plan to reduce expenses, including a 20% workforce reduction, with estimated restructuring charges of $25 million
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →